Free Trial
OTCMKTS:GBLX

GB Sciences (GBLX) Stock Price, News & Analysis

GB Sciences logo
$0.0004 +0.00 (+33.33%)
As of 06/13/2025 12:34 PM Eastern

About GB Sciences Stock (OTCMKTS:GBLX)

Key Stats

Today's Range
$0.0004
$0.0004
50-Day Range
N/A
52-Week Range
$0.0001
$0.0135
Volume
100 shs
Average Volume
75,536 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Receive GBLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter.

GBLX Stock News Headlines

GB Sciences Reports Delay in Quarterly Filing
[Wanted] 250 intrepid souls
He Called this 106X Opportunity Before Reddit… and Before Elon Musk Before GameStop rocketed up to 10,633, Jonathan Rose saw something strange: A sudden surge in options volume — thousands of contracts flooding in. The money hit deep inside the CBOE before Reddit posts created the short squeeze and before Elon's tweet sent GameStop flying. Jonathan calls it the "Big-Money Tell," and it's flagged dozens of big trade opportunities including: 462.5% in C3.ai, 245.13% in Criteo, and 39.46% in Roku. And these are just some of the gains the "tell" has identified. Even better: He says the next big set-up could be forming right now. And there's still time for you to get in before it kicks off as soon as seven days from now.
GB Sciences, Inc. (GBLX) stock forecast and price target
GB Sciences Inc (GBLX)
See More Headlines

GBLX Stock Analysis - Frequently Asked Questions

GB Sciences' stock was trading at $0.0040 at the start of the year. Since then, GBLX shares have decreased by 90.0% and is now trading at $0.0004.
View the best growth stocks for 2025 here
.

GB Sciences, Inc. (OTCMKTS:GBLX) announced its earnings results on Monday, November, 14th. The company reported ($0.04) EPS for the quarter.

Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GB Sciences investors own include Canopy Growth (CGC), 22nd Century Group (XXII), NVIDIA (NVDA), Unrivaled Brands (TRTC), Trees (CANN), Aurora Cannabis (ACB) and Meta Platforms (META).

Company Calendar

Last Earnings
11/14/2016
Today
6/15/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
Cannabis
Current Symbol
OTCMKTS:GBLX
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:GBLX) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners